Fundraising FoxFannin Goldenrod Holdings — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Goldenrod Therapeutics develops brain-penetrant phosphodiesterase 4 inhibitors for neurological and neuropsychiatric disorders, focusing on overcoming tolerability limitations of earlier PDE4 inhibitors to address neuroinflammation.
BiotechDeep TechHealthtechMedical DevicesHouston, US
Corey Hopkins(Chair of the Department of Pharmaceutical Sciences and Director of the Center for Drug Design and Innovation at UNMC)Dev Chatterjee(Executive Officer)inLeo Linbeck IV(Executive Officer)Mark Worscheh(Executive Officer, Director)in
BoardAtul Varadhachary(Executive Officer, Director)
Board seatLeo Linbeck III· per SEC Form D · $6.5M raise · filed Jun 2026
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.